Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ahj.2009.05.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Complement activation as a biomarker for platelet activating antibodies in heparin-induced thrombocytopenia (HIT).
J Thromb Haemost
December 2024
Division of Hematology, Duke University Medical Center, Durham, NC. Electronic address:
Background: IgG antibodies (Abs) to platelet factor 4 complexed to heparin (PF4/H) commonly occur after heparin exposure but cause life-threatening complications of heparin-induced thrombocytopenia (HIT) in only a few patients. Presently, only platelet activation assays reliably distinguish anti-PF4/H Abs that cause disease (HIT Abs) from those likely to be asymptomatic (AAbs).
Objectives: Recent studies indicate that complement activation is an important serologic property of HIT Abs and is essential for FcγRIIA-mediated cellular activation.
Is the combination of two automated rapid assays for diagnosis of heparin-induced thrombocytopenia necessary?
Blood Coagul Fibrinolysis
December 2024
Clinical Biochemistry Laboratory, Provincial Hospital of Bolzano (SABES-ASDAA), Bolzano, Italy.
Heparin-induced thrombocytopenia (HIT) is an immune-mediated condition characterized by a decrease in platelet count and an increased thrombotic risk. HIT event is caused by antiplatelet factor/heparin (PF4/H) antibodies that can activate the platelets. The diagnosis of HIT is based on a clinical evaluation and laboratory results.
View Article and Find Full Text PDFHeparin-induced thrombocytopenia with very high antibody titer is associated with slower platelet recovery and higher risk of thrombosis.
Int J Hematol
September 2024
Department of Hematology and Oncology, Houston Methodist Hospital, Houston, TX, USA.
Heparin-induced thrombocytopenia (HIT) is a prothrombotic disorder mediated by platelet-activating antibodies targeting platelet factor 4 (PF4) and heparin complex. A higher antibody titer is reflected in a higher optical density (OD) by enzyme-linked immunosorbent assay for heparin-PF4 antibodies. This single-institution retrospective study of 116 HIT patients examined the effect of heparin-PF4 OD on time to platelet recovery, vascular thrombosis, and in-hospital mortality.
View Article and Find Full Text PDFIntraoperative Bivalirudin Use in Patient Undergoing Femoral Endarterectomy with Heparin-Induced Thrombocytopenia: Case Report and Review of the Literature.
Vasc Endovascular Surg
April 2024
Department of Pharmacy, UK HealthCare, Lexington, KY, USA.
Purpose: To describe the intraoperative use of bivalirudin during lower extremity revascularization in the setting of heparin-induced thrombocytopenia (HIT).
Case Summary: A 65 year-old man presented with left common iliac, external iliac, and femoral artery occlusion necessitating revascularization with left femoral endarterectomy and common and external iliac stent angioplasty. Three months before the femoral endarterectomy, the patient was hospitalized for a coronary artery bypass procedure.
A Functional Assay for the Determination of Heparin-Induced Thrombocytopenia via Flow Cytometry.
Diagnostics (Basel)
September 2023
Institute of Hematology and Blood Transfusion in Prague, 128 20 Nove Mesto, Czech Republic.
Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin therapy (both unfractionated heparin and low-molecular-weight heparin). In our study, we examined a group of 122 patients with suspected HIT. The samples of all patients were analyzed in the first step using an immunoassay (ID-PaGIA Heparin/PF4, Hemos1L-Acustar HIT IgG, ZYMUTEST HIA Monostrip IgG) to detect the presence of antibodies against heparin-PF4 complexes (platelet factor 4).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!